Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Core Technology
Materials & SubstancesNanomaterialsBiologicalsCells
Tags (7)
biotechnologymedical-technologiestherapeuticsoncologycancercell-therapynanotechnology
AnserBio Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
$750KDec 2021
$4.8MDec 2023
$4.8MJan 2020
$5.0MJan 2021
$5.7MJul 2023
$6.5MNov 2022
Private Equity Funding
Israel Biotech Fund (Lead)
AnserBio Lifecycle
Cumulative Funding Raised Over Time
$750KDec 2021
$4.8MDec 2023
$4.8MJan 2020
$5.0MJan 2021
$5.7MJul 2023
$6.5MNov 2022
All Events
Israel Biotech Fund (Lead)
AnserBio News
1 article
Fighting cancer from within
ExoProTher Medical, a company developing a new approach to cancer treatment, is closing a seed funding round. The company utilizes the p53 protein, which is recognized as a genome protector, to treat brain cancer. The treatment involves injecting animal protein in the form of nanoparticles. The company has completed a $1 million seed private placement and has raised about $700,000 to date. They are also running a crowdfunding campaign to raise additional funds. ExoProTher Medical plans to begin human trials for their product within three years.
Investment
AnserBio Team
Lana Volokh
Co-founder & CEO
Founder
Dr. Alex Tendler
Co-founder & CTO
Founder
Employee Info
| Employees (range) | 1-10 |
| Exact count | 7 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.